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ABSTRACT  
 
Background Hemodialysis (HD) patients elicit an oxidant-antioxidant imbalance in 
addition to a selenium deficiency, possibly contributing to cardiovascular disease (CVD) 
mortality.  
Objective To evaluate the effect of selenium supplementation on CVD outcomes and 
antioxidant status in HD patients.  
Design A randomized controlled intervention trial conducted from October 2012 to 
January 2013.  
Participants/setting The study included 27 maintenance HD patients (61.1+17.5y, 14M, 
13F) receiving HD in the greater Phoenix, AZ area. 
Intervention Patients received one of three treatments daily: 2 Brazil nuts, (5g, 
181µg/day of selenium as selenomethionine [predicted]), 1 tablet of selenium (200µg/day 
of selenium as selenomethionine), or control (3 gummy bears).  
Main outcome measures Antioxidant status outcome measures included total 
antioxidant capacity, vitamin C, and RBC and plasma glutathione peroxidase (GSH-Px). 
CVD outcomes measures included brain natriuretic peptide; plasma cholesterol, high 
density lipoprotein, low density lipoprotein, triglycerides; blood pressure, and thoracic 
cavity fluid accumulation.  
Statistical analyses performed Repeated measures ANOVA analyzed changes over time 
and between groups at months 0 and 2 and months 0 and 3. 
Results Independent analysis showed the Brazil nuts provided 11µg of selenium/day and 
the pill provided 266µg of selenium/day. Consequently, the Brazil nut group was 
combined with the placebo group. 21 patients completed 2 months of the study and 17 
ii 
patients completed the study in its entirety. Data was analyzed for months 0, 1 and 2. No 
significant differences were noted for antioxidant status outcome measures with the 
exception of plasma GSH-Px. Patients receiving the selenium pill had a significant 
increase in plasma GSH-Px compared to the placebo group (6.0+11 and -4.0+7.6, 
respectively, p=0.023 for change between month 0 and month 2). No significant 
differences were seen in total antioxidant capacity or for CVD outcome measures over 
time or between groups.  
Conclusions These data indicate that selenium supplementation increased plasma GSH-
Px concentration in HD patients; however, oxidative stress was not altered by selenium 
supplementation.  The low vitamin C status of HD patients warrants further research, 
specifically in conjunction with selenium supplementation. 
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Chapter 1 
 
INTRODUCTION 
 
Overview 
The escalating number of deaths per year related to kidney disease is troubling. All-
cause mortality among current end stage renal disease (ESRD) dialysis patients (adjusted 
for age and gender) per 1,000 patient years is 154 and 313 for patients aged 45-64y and 
65+, respectively.
1
 The major cause of death in patients with kidney failure is 
cardiovascular disease (CVD). In the existing dialysis population, 39% of deaths are 
attributable to cardiac disease, and in hemodialysis patients, 84.7 deaths per 1000 patient 
years are due to cardiovascular mortality.
1
 
Intervention trials using conventional therapies to improve CVD risk (e.g., lipid 
lowering medications) have been successful in improving lipid markers, such as plasma 
low density lipoproteins, cholesterol and triglycerides, however have been unsuccessful 
in decreasing mortality rates in hemodialysis (HD) patients; however, several trials that 
utilized antioxidant therapies demonstrated reduced CVD events in HD patients.
2
 
Antioxidant capacity is impaired in the hemodialysis population
3, 4
 leading to elevated 
oxidative stress.
5
 Glutathione peroxidase (GSH-Px) is a potent free radical scavenger that 
specifically reduces hydrogen peroxide and protects cells from oxidative damage. Plasma 
GSH-Px is made primarily in the proximal tubular cells of the kidney
6, 7
 with small 
amounts made in other tissue, including the liver, lung, heart, intestine, brain, and skeletal 
muscle.
7, 8
 Once made, it is secreted into the extracellular fluid.
7
 Research shows both 
plasma and red blood cell (RBC) GSH-Px are reduced in patients with chronic kidney 
disease (CKD) compared to their healthy counterparts.
9, 10
 Selenium is required for GSH-
 2 
Px function and has also shown to be reduced in HD patients.
11
 This deficiency of 
selenium in HD patients may be due to selenium lost in dialysate
11
 however this research 
is inconclusive.
12
 
Selenium is found in foods in two forms: organic and inorganic. The inorganic forms 
are mainly found in supplements and some plant foods. The three forms of inorganic 
selenium include selenite, selenate, and selenide. The organic forms are found in food, 
with selenium replacing the sulfur component of two specific amino acids, resulting in 
either selenomethionine (plant foods) or selenocysteine (animal foods). Specifically in 
HD patients, selenium supplementation using an inorganic form of selenium has 
demonstrated inconsistent results regarding its effect on both plasma and RBC GSH-Px. 
Several researchers found plasma selenium to increase with selenium supplementation 
(using the both the organic and inorganic form);
10, 13-15
 however, only two studies
10, 16
saw 
an improvement in red blood cell GSH-Px, while Zachara et al
14
 and Temple et al
13
 did 
not find a significant change in plasma GSH-Px after supplementation.  
It is believed the results vary because of the selenium form used in supplementation. 
The above studies have used either inorganic forms of selenium for supplementation, or 
have used selenium-rich yeast which is rich in selenomethionine. In healthy adults, 
research has shown selenomethionine supplementation from a natural food source, Brazil 
nuts, significantly improved whole blood GSH-Px compared to a selenomethionine 
tablet.
17
 A study involving dialysis patients was conducted in Brazil by Stockler-Pinto et 
al
15
 in which selenium supplementation, in the form of selenomethionine from a Brazil 
nut, showed improved plasma selenium and RBC GSH-Px. While this is valuable 
information, greater contribution to the literature is warranted, specifically determining if 
 3 
organic selenium supplementation from food will have significant effects not only on 
plasma and RBC GSH-Px, but on more specific cardiovascular endpoints, including brain 
natriuretic peptide (BNP), a hormone used to determine heart failure, along with 
antioxidant measures, including total antioxidant capacity and plasma vitamin C. 
Interestingly, previous studies evaluating the effect of selenium supplementation on 
cardiovascular endpoints in HD patients have not examined its effect on BNP.  This 
knowledge would contribute immensely to the current research, and with the expanded 
cardiovascular and antioxidant endpoint information, hemodialysis treatment could be 
significantly altered and decreased mortality is quite possible.   
Statement of Purpose 
 
The purpose of this randomized controlled trial in hemodialysis patients is 
threefold. The first aim is to evaluate the effect of selenium supplementation on 
cardiovascular disease outcomes in hemodialysis patients. The second aim is to determine 
the effect of selenium supplementation on antioxidant status in hemodialysis patients. 
The third aim is to compare the effect of selenium supplementation from a food source 
versus a supplement on antioxidant and cardiovascular disease outcomes in hemodialysis 
patients. 
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Hypotheses 
 
The primary hypothesis of this research is that selenium supplementation 
compared to control will independently improve cardiovascular disease outcomes in 
hemodialysis patients as measured by thoracic cavity bioimpedence; brain natriuretic 
peptide; blood pressure; plasma low density lipoprotein, high density lipoprotein, total 
cholesterol and triglycerides.   
The secondary hypothesis of this research is that selenium supplementation 
compared to control will independently raise antioxidant status in hemodialysis patients 
as measured by plasma total antioxidant capacity, plasma vitamin C,  plasma glutathione 
peroxidase, and red blood cell glutathione peroxidase.   
The tertiary hypothesis of this research is that selenium from a natural food source 
(Brazil nut) will independently improve biomarkers, including thoracic cavity 
bioimpedence; brain natriuretic peptide; blood pressure; plasma low density lipoprotein, 
high density lipoprotein, total cholesterol, triglycerides; plasma total antioxidant capacity, 
plasma vitamin C; and plasma and red blood cell glutathione peroxidase in hemodialysis 
patients to a greater degree than selenium from a supplemental source (selenomethionine 
tablet).    
Definition of Terms 
 
Brain Natriuretic Peptide (BNP): a protein containing 32 amino acids secreted by the 
cardiomyocytes as a result of increased left ventricular mass; BNP is used to diagnose 
heart failure.
18
 
 5 
Glutathione Peroxidase (GSH-Px): a human enzyme responsible for dissipating hydrogen 
peroxide; GSH-Px is considered the second line of defense in the antioxidant defense 
system and requires selenium to function.
19
 
Total Antioxidant Capacity (TAC): the cumulative action of glutathione, ascorbic acid, 
vitamin E, bilirubin, trolox, bovine serum albumin, and uric acid in body fluids and 
plasma.
20
 
 
Delimitations and Limitations 
 
The study was conducted with maintenance hemodialysis patient from the 
Phoenix, Arizona area. Therefore, the results of the study can only be generalized to a 
similar patient population. In addition, the study contains a small sample size of 30 
participants due to financial constraints. Furthermore, other markers of cardiovascular 
disease (e.g. Troponin T), measures of lipid peroxidation (e.g. malonlydialdehyde and 
thiobarbituric acid reactive substances), and vitamin E would have been useful however 
the cost exceeded financial capabilities.    
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Chapter 2 
 
REVIEW OF LITERATURE 
 
Free Radicals and Antioxidants 
Development of Free Radicals 
Oxidative stress can be defined as an excessive production of reactive oxygen 
species, an extremely reactive molecule, or inadequate removal these reactive oxygen 
species.
21
 Oxidative stress is generally thought of as a negative reaction in the human 
body. On the contrary, it is necessary for defense against invading microorganisms as 
well as tissue repair and inflammation. However, in an uncontrolled environment, 
oxidative stress can be harmful.
22
 Briefly, neutrophils and monocytes-macrophages 
increase oxygen (O2) consumption, resulting in the formation of superoxide (O2-). 
Production of this radical can either be from normal physiologic processes or external 
stimuli, such as ozone or ethanol.
23
 Superoxide can combine with nitric oxide, a reactive 
nitrogen species,
24
 to form other toxic nitrogen species, such as peroxynitrite (ONOO-), 
or it can be converted to hydrogen peroxide (H2O2). Hydrogen peroxide, which is not 
extremely harmful itself,
19
 can then react with intracellular iron to produce hydroxyl 
radicals (OH-), or it can react with chloride to produce hypochlorous acid (OCl).
22
 These 
reactive molecules (OH-, ONOO-, OCl-, etc), collectively termed reactive oxygen species 
(ROS), in conjunction with pro-inflammatory cytokines will increase the generation of 
oxidants, resulting in lipid cell membrane breakdown, DNA damage and protein 
accumulation.
19
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Antioxidant Defense System 
The human body has a strong antioxidant defense system, which helps to dissipate the 
harmful reactive oxygen species (ROS). The three main enzymatic antioxidant systems 
are superoxide dismutase (SOD), catalase, and glutathione peroxidase (GSH-Px). As a 
first line of enzymatic defense, SOD, present in the mitochondrial matrix and cytosol, 
catalyzes the conversion of superoxide (O2
-
) to hydrogen peroxide (H2O2) and oxygen 
(O2), dissipating the superoxide molecule, a harmful free radical. Catalase and GSH-Px 
are considered the second line of defense. Catalase works to convert hydrogen peroxide 
into water (H2O) and oxygen (O2) and is found throughout most of the body. GSH-Px is 
required to reduce organic lipid hydroperoxides as well as hydrogen peroxide.
19
 
Specifically, GSH-Px, in conjunction with reduced glutathione (GSH), catalyzes 
hydrogen peroxide to oxidized glutathione and two molecules of water. This reaction can 
continue only if other vitamins and components are present. Specifically, riboflavin and 
niacin are necessary for glutathione reductase to reduce oxidized glutathione back to 
GSH (See figure 1). The human body also has nonenzymatic antioxidant systems to 
defend against harmful free radicals. The four major nonenzymatic radical scavengers are 
glutathione, vitamin C, vitamin E, and certain proteins.
19
 Glutathione, mentioned above 
as reduced glutathione, is found in all cell types. It converts hydrogen peroxide to water 
with the enzyme glutathione peroxidase. Vitamin C is found all throughout the body
19
 
and is a potent antioxidant. Vitamin C, or ascorbic acid, reduces free radical molecules, 
resulting in semidehydroascorbic acid,
19
 followed by formation of dehydroascorbic acid. 
GSH, in conjunction with the enzyme dehydroascorbate reductase, regenerate ascorbic 
acid by reducing dehydroascorbic acid. The regeneration of ascorbic acid allows the 
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molecule to continue to neutralize free radicals.
25
 Research has shown vitamin C 
supplementation maintains blood glutathione levels and improves antioxidant capabilities 
in the blood.
26
 Vitamin E is found in cell membranes and protects cells against lipid 
membrane peroxidation. Specifically, it protects the unsaturated fatty acids in the 
phospholipids of the cell membrane.
25
 Using the reducing potential of a hydroxyl group (-
OH), vitamin E can inhibit the damaging radical cascade that takes place in the lipid 
membrane, most notably the peroxyl radicals.
25
 The result is a vitamin E radical that must 
be reduced in order to be reused. The recycling of vitamin E is dependent on reduced 
glutathione and vitamin C.
25
 Figure 2 demonstrates the synergism of glutathione, vitamin 
C and vitamin E as antioxidants. Lastly, certain proteins, including albumin, transferrin, 
ceruloplasmin and ferritin, can aid in the antioxidant process.
19
 Albumin is found in the 
plasma and plays a large role in binding and transporting molecules throughout the body. 
Albumin binds a host of molecules, including the divalent cations calcium and 
magnesium, bile acids, zinc, copper, and folate, to name a few.
27
 Transferrin is a transport 
protein that transports iron in the oxidized, ferric (+3) form. Ceruloplasmin is a copper-
containing enzyme responsible for converting iron into the ferric from in order to bind to 
transferrin, whereas ferritin stores iron in the ferric form until the body requires its use. 
These proteins aid in limiting oxidative stress by binding transition metal ions, such as 
ferric iron, to minimize the production of free radicals.
19
 The intricate antioxidant system 
the human body has developed is complex and interdependent on many nutrients.  
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Figure 1. The Glutathione Oxidation Reduction Cycle
a 
aImage courtesy of Linus Pauling Institute, Oregon State University, Corvallis, OR 
 
 
 
 
 
Figure 2. The interaction between glutathione, vitamin E and vitamin C in the 
antioxidant defense system
b 
bImage courtesy of Me van Meeteren et al28 
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Selenium 
Selenium Nutriture  
Selenium is a nonmetal that is required for a number of enzymatic, namely 
antioxidant, functions in the human body
25
 making it an important nutrient for controlling 
oxidative stress levels. Selenium can be found in both plant and animal sources. There are 
two forms of selenium: organic and inorganic. The two organic forms are selenocysteine 
and selenomethionine. Of the twenty amino acids, methionine and cysteine are the only 
sulfur containing amino acids. The sulfur incorporated in each of these amino acids can 
be displaced by selenium, resulting in either selenocysteine or selenomethionine (See 
figure 3). Selenocysteine and selenomethionine are typically found in animal and plant 
products, respectively.
25
 Because plants do not require selenium, the element is 
incorporated into methionine by substituting selenium for sulfur, resulting in 
selenomethionine.
29
 The amount of selenium from a plant or plant food product varies 
significantly depending on the soil. Selenium is found in the soil and transferred to the 
plant product when it grows.
29
 Therefore, depending on where the plant grows, the 
amount of selenium in the product can differ drastically
30
 – up to a ten-fold difference.29 
Consequently, the animal eating the plant will also ingest a varying amount of selenium 
due to selenium soil content.
29, 30
 The amount of selenium from animal products, typically 
as selenocysteine, also differs significantly due to the varying amount of selenium 
ingested when the animal ate the plant product.
29
 As mentioned above, animal products 
typically contain selenocysteine as the main source of selenium. It is important to note 
this is the biologically active form in animals and humans.
29
 The inorganic forms of 
selenium include selenite, selenate, and selenide. These forms of selenium can be found 
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in certain vegetables, however they are mostly found in supplements, typically in the 
form of selenate, selenite or selenomethionine.
25
 The recommended dietary allowance for 
selenium is 55µg/day for adults.
31
 
 
Figure 3. Sulfur containing selenocysteine and selenomethionine
c 
 
c 
Image courtesy of Shils et al 32 
The bioavailability of selenium differs with source; however, overall the mineral 
is highly available. Approximately 80 percent of organic selenium is absorbed, primarily 
in the duodenum with small amounts absorbed in the jejunum. It is thought that 
selenomethionine is better absorbed than selenocysteine
25
 and that the absorption follows 
the same pathway as methionine. Among inorganic forms of selenium, selenate is better 
absorbed than selenite however selenite is better retained in the body compared to 
selenate.
33
    
After initial ingestion, the various forms of selenium are metabolized differently. 
Specifically, selenium ingested as selenomethionine has three fates: it can be used for 
protein synthesis, recognized as methionine and stored in the amino acid pool, or 
catabolized to selenocysteine.
25
 The other organic form of selenium, selenocysteine (from 
food consumption or degradation of selenomethionine), may be catabolized to free 
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selenium which is then reduced to form selenide.
25
 Selenide has one of two fates: it will 
be phosphorylated to selenophosphate, or methylated to be excreted in the urine. If 
converted to selenophosphate, the molecule will be used for the synthesis of 
selenocysteine in the liver.
34
 In fact, selenophosphate must undergo a reaction with serine 
to form selenocysteine which can be added to peptide chains of specific selenium-
dependent enzymes, including GSH-Px.
25
 Ingested selenocysteine cannot be used directly 
for selenium-dependent enzyme synthesis, also called selenoproteins, however it can be 
incorporated into selenium-containing proteins.
35
 A selenoprotein is one in which 
endogenously synthesized selenocysteine is formed and incorporated into proteins, 
whereas a selenium-containing protein is one in which selenium is not in its biologically 
active and functional form (i.e: selenomethionine).
36
 The inorganic forms of selenium 
must be converted to selenophosphate to be used for selenoprotein synthesis in the liver.
34
    
Selenium is mainly found in the kidney and liver with smaller amounts in the 
heart muscle, skeletal muscle, brain and nervous tissue. When selenium intake is low, the 
liver and blood amounts tend to decrease first whereas kidney concentrations are not as 
affected.
37
 Selenium is stored in two pools in the human body.
29
 The first is selenium as 
selenomethionine, which is dependent on dietary intake and is not dependent on the 
body’s need for selenium, but rather a function of methionine turnover.38 The second 
body pool is located in the liver
29
 and is termed the exchangeable metabolic pool, in 
which all forms of selenium that contribute to functional uses of selenium containing 
compounds are stored, including GSH-Px and selenoprotein P.
34
 Interestingly, as 
selenium intake decreases, synthesis of liver GSH-Px is reduced, allowing selenium 
availability for synthesis of other selenoproteins.
29
 Approximately 10% of selenium is 
 13 
excreted in feces with the majority of the remainder excreted in the urine as urinary 
metabolites.
39
 
Selenium in the Antioxidant Defense System  
Selenium is a pivotal part of the human antioxidant system. As mentioned above, 
GSH, or reduced glutathione, is needed to reduce hydrogen peroxide resulting in water 
and oxidized glutathione. This reaction cannot occur without the enzyme GSH-Px which 
is dependent on selenium.
40, 41
. GSH-Px is found throughout the body, including the red 
blood cells, lungs, heart, kidney and liver.
42
 Research has shown a deficiency in either 
selenium or GSH-Px will result in membrane damage and protein dysfunction.
43
 As 
previously mentioned, vitamin C and E play a crucial role in antioxidant function in 
association with GSH. Furthermore, the regeneration of both vitamin E and C require 
GSH and glutathione dehydrogenase. Hence, adequate vitamin C status will spare GSH 
and help to regenerate vitamin E thereby maximizing antioxidant protection
44
; a 
deficiency in vitamin E can result in neurological damage
45
 while a deficiency in vitamin 
C can be fatal.
46
   
In addition to GSH-Px, selenium is required for a number of other molecules in 
the body. Of the three types of deiodinases, which are responsible for thyroid hormone 
activation and deactivation, selenocysteine has been shown to be the active site of type 1 
deiodinase and type 3 deiodinase. These deiodinases are responsible for regulating 
activation and deactivation of 3,4,3’-triiodothyronine, or T3, which is involved in brain 
development and growth.
47
 Selenocysteine is also the active site for selenoprotein P, 
which is comprised of ten selenocysteine residues
48
 and is the major selenium containing 
protein in the plasma.
25
 While once thought of as a selenium transport protein, 
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selenoprotein P is a glycoprotein that functions as an extracellular antioxidant dissipating 
peroxynitrite, a reactive nitrogen species.
49
 Finally, thioredoxin reductase is an enzyme 
containing selenium in the form of selenocysteine, required for the growth of cells.
48
  
Selenium Toxicity  
 While diminished levels of selenium can be detrimental to the body, toxic intake 
of selenium can also be deleterious. The Dietary Reference Intake has set the upper limit 
for adults for selenium consumption at 400µg/day due to brittleness and loss of hair and 
nails.
31
 At very high levels, selenium can be considered a prooxidant inducing 
oxidation.
50
 Certain selenium compounds can induce generation of superoxide while 
others do not. The selenium compounds that result in the generation of superoxide 
include selenite, selenocysteine, and selenium dioxide, while selenate, selenomethionine, 
and elemental selenium do not induce the generation of superoxide.
50-52
 The inorganic 
forms of selenium react with tissue thiols
53
 resulting in selenotrisulphides. The newly 
formed selenotrisulphides further react with the oxidized thiols forming superoxide.
50
 
Another plausible reason for selenium causing oxidative stress suggests higher levels of 
selenocysteine inhibit the methylation of selenium for urine excretion, causing an 
increased concentration of the hydrogen-selenide, resulting in the formation of 
superoxide.
50
 Lastly, selenium may assist in reactions leading to the formation of reactive 
selenium-containing intermediates.
54
 Nonetheless, selenium toxicity is a result of 
increased oxidative damage exceeding the capacity of the antioxidant defense system
52
 
causing DNA damage.
55
  
 While selenium is valuable to sustain the antioxidant defense system, it can also 
be a prooxidant, increasing oxidative stress. While this sounds detrimental, it may be a 
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benefit to the body. In fact, researchers have suggested selenium has the potential to be 
used in conjunction with anticancer drugs or radiation to improve the efficacy of the 
treatment, in addition cancer prevention.
56
 The organic form of selenium, specifically 
selenomethionine, when injected into human tumor cell lines, including breast carcinoma, 
prostate cancer cells and melanoma, was found to causes apoptosis, or cell death.
57
 
Further, when evaluated in vitro on human breast carcinoma cells, the tumorigenic 
mammary epithelial cells were highly sensitive to selenocysteine and selenomethionine, 
resulting in apoptosis. Interestingly, the non-tumorigenic cells did not experience 
apoptosis until a significantly higher dose was given.
58
 Additionally, selenium has been 
shown to suppress melanoma cells while inhibiting the growth of tumors in the lung, also 
due to apoptosis.
59
 Conversely, research has also shown selenium to be detrimental as a 
prooxidant. In a 12 day trial, mice were supplemented with selenite. Results showed 
selenium supplementation increased malonyldialdahyde, a measure of lipid peroxidation, 
and decreased glutathione, and the antioxidants superoxide dismutase and catalase.
60
 For 
otherwise healthy adults, when evaluating serum selenium concentration and mortality, a 
recent review suggest a U-shaped link such that those with a high selenium status and 
low selenium status have increased all-cause mortality. Additionally, supplementation of 
those with a relatively high level of serum selenium may increase their risk of type 2 
diabetes.
61
 
Selenium and Cardiovascular Disease 
Selenocysteine, the biologically active form of selenium and sometimes referred to as 
the 21
st
 amino acid,
62
 is required for many enzymatic, namely antioxidant, functions in 
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the human body as discussed previously. A deficiency in the above trace element will 
produce harmful effects, including cardiovascular disease, in otherwise healthy adults.  
Two diseases have been linked to and caused by a selenium deficiency: Keshan 
Disease (KD) and Kashin-Beck Disease (KBD). KD results in cardiomyopathy 
whereas KBD results in osteoarthropathy. KD dates back to 1935 when an outbreak 
occurred in Keshan County, China. The effects of the disease resembled the plague and 
mostly affected women of child-bearing age and infants after weaning.
63
 During the 
1960’s, a selenium deficiency occurring in livestock, called white muscle disease 
(WMD), was also observed in the areas of those affected with KD. Researchers noticed 
the similarities between WMD and KD, supplemented human patients with selenium, in 
the form of selenite, and vitamin E in the hopes that KD would be prevented; however, 
no clear results were extracted from study.
63
 More research was conducted in the early 
1970’s. Researchers measured blood and hair selenium concentrations and collected diet 
records to determine selenium intake and saw a connection between KD and selenium 
deficiency.
63
 Further research showed hair selenium,
64
 and selenium concentration of the 
heart, muscle, liver and kidney
65
 of the affected area was significantly lower than non-
KD affected areas. To further research this problem, scientists gave high-risk children 
either sodium selenite tablets or placebo. The children receiving the treatment had 
significantly less death than those receiving the placebo.
64
 It is worth mentioning the 
severity of KD was shown to be proportional to the extent of the selenium deficiency.
66 
Researchers have concluded that while selenium is essential, it is not the only 
cause of KD. This is evident by hair selenium of various parts of China in which areas 
that developed KD had the same low selenium status as areas that did not develop KD.
66
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Additionally, a seasonal variation was seen with KD development.
66
 It is now accepted 
that a selenium deficiency plays a major role in KD as well as coxsackie virus infection. 
Of the sixteen coxsackie viruses, coxsackie virus B3 has been shown to contribute to the 
development of KD, resulting in myocarditis.
67
 
 Currently, selenium deficiency is rare among most of the world, and only seen in 
KD affected China.
63
 As mentioned above, selenium is crucial for antioxidant function 
and as expected, the person infected with KD experiences an extreme impairment in their 
antioxidant defense system due to the selenium deficiency. They also experience death of 
the myocardium as an outcome of injury to cell membranes and proteins.
63
 Although KD 
is now considered rare, it is still noteworthy to evaluate if selenium status can predict 
and/or prevent heart disease.   
 Many different types of studies have been conducted to evaluate if selenium status 
is related to heart disease and death in participants without KD, however the results vary 
widely and are inconclusive. In a cross sectional study, Kok et al compared plasma, red 
blood cell and toenail selenium in participants with and without acute myocardial 
infarctions from the Netherlands. They found levels of all three markers to be 
significantly lower in those with acute myocardial infarctions than those without. 
Additionally, the authors noted the diminished selenium levels were present before the 
infarction occurred as evidenced by the low toenail selenium levels, as toenail selenium is 
reflective of long term status, up to one year. These data indicated that selenium 
contributes to CVD etiology.
68
 A longitudinal study involving over 8000 men and women 
of Finland investigated serum selenium and risk of death. The study used data from 
patients who died from any type of heart disease or experienced a non-fatal myocardial 
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infarction over a seven year follow up period, and compared the values to matched 
healthy controls. The results showed those who died of heart disease or had a non-fatal 
MI had significantly lower serum selenium. Additionally, the relative risk associated with 
a serum selenium of <45µg/l for CHD death, CVD death, and fatal and non-fatal MI were 
all 2 times more likely than that of healthy controls (p<0.01). Additionally, serum 
selenium was attributed to 22% of deaths in the study population.
69
 In a prospective 
study, Wei et al found no significant increase in death due to heart disease or stroke in 
relation to serum selenium at baseline after a 15 year follow up period in over 1100 
subjects.
70
 In a thirteen-year intervention period, researchers supplemented patients free 
from cardiovascular disease with 200µg selenium/day as selenium-rich yeast. 
Cardiovascular disease and mortality was assessed however no statistical significance 
was found between treatment and above mentioned CVD endpoints. It is noteworthy that 
this study was a subset of the Nutritional Prevention of Cancer Trial and thus, while 
participants were free from CVD, they had a history of nonmelanoma skin cancer within 
one year of randomization.
71
 Finally, Flores-Mateo et al conducted a meta-analysis 
evaluating the association between selenium biomarkers and coronary heart disease 
endpoints using observational studies, and the effectiveness of selenium supplementation 
in coronary heart disease prevention using randomized trials. Observational study results 
showed a 50% increase in selenium concentrations was associated with a 24% reduction 
in risk of coronary heart disease. Results of the randomized controlled trials showed an 
11% decrease risk of coronary heart disease when comparing selenium supplements to 
placebo, although not significant. The authors suggest that while the observational studies 
showed an inverse relationship between selenium and coronary heart disease, and only a 
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few randomized control trials have been conducted regarding selenium and coronary 
heart disease with inconsistent results, more research is needed and selenium 
supplementation should not be recommended at this time.
72
  
 Selenium is an integral part of the human antioxidant system and a deficiency in 
the mineral causes severe problems as evidenced by the cardiomyopathy seen with KD 
affected people. However, selenium supplementation trials have not shown an 
overwhelming response and subsequent decrease in heart disease. It may be that 
supplementation is only effective in those with a deficiency.  
End Stage Renal Disease 
End Stage Renal Disease, Cardiovascular Disease and Antioxidant Status 
Dialysis patients present with many physiological problems due to the nature of 
their disease and the diminished homeostatic regulatory ability of the kidney. Besides a 
kidney transplant, two dialysis treatment options are available: hemodialysis and 
peritoneal dialysis. Hemodialysis (HD) uses an extracorporeal filtration system to remove 
toxic waste from the body, and peritoneal dialysis uses the individual’s peritoneal cavity 
as a filter to remove toxic waste. While treatment, specifically HD, can be an effective 
tool in removing harmful waste products, it can also be detrimental leading to 
cardiovascular disease (CVD).  
 End stage renal disease (ESRD) patients present with uremia, or buildup of 
nitrogenous waste products, including urea nitrogen and creatinine, in the blood. To 
remove these harmful toxins, dialysis or transplantation is needed. Hemodialysis is the 
most common form of treatment to date.
1
 The patient’s blood is circulated through an 
extracorporeal filtration system and returned to the body during the HD treatment. While 
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this process removes urea from the body, it does not correct all abnormalities seen with 
ESRD and it has been suggested to cause increased oxidative stress and decreased 
antioxidant capacity, leading to other harmful diseases, such as CVD. CVD development 
starts with oxidation of lipoproteins in the arterial wall and the release of 
malondialdehyde (MDA), short chain aldehydes that are byproducts of lipid peroxidation, 
along with other aldehydes. These molecules can alter residues of apolipoprotein B, a 
component of low density lipoproteins (LDL). As a result, the newly altered LDL 
contributes to the formation of foam cells by being consumed by macrophages in the 
subendothelial space.
73, 74
 This, in turn, triggers a series of reactions to initiate 
atherosclerotic plaque formation. Over time, the narrowing of the arteries diminishes 
blood flow to vital organs, including the heart and kidney.
73
 
Research has shown both antioxidant pathways (enzymatic and non-enzymatic) in 
patients with chronic renal failure and on dialysis to be significantly impaired.
3
 
Specifically, serum selenium, glutathione peroxidase, and vitamin C were lower in 
chronic renal failure (CRF) and HD patients compared to healthy controls. Interestingly, 
this decrease was exacerbated by the treatment of HD as patients with HD treatment had 
lower serum levels of glutathione peroxidase and vitamin C, and higher levels of MDA 
compared to CRF patients.
3
 Moreover, the dialysis process induces oxidative degradation 
of membrane lipids.
75
 With respect to vitamin C, Morena et al found ~65mg of vitamin C 
was lost each dialysis session,
76
 exacerbating the risk for low antioxidant status. 
Additionally, Koenig et al
77
 found the same to be true: HD patients presented with an 
impaired free radical scavenger system with increased MDA. Furthermore, they also 
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found the enzymatic antioxidant pathway to be significantly impaired as evidenced by 
decreased RBC GSH-Px.  
Impairment of the Oxidant-Antioxidant Balance 
It has been suggested the greater impairment of the oxidant-antioxidant balance in 
HD patients compared to CRF patients is because the process of an extracorporeal 
filtration system (hemodialysis) results in blood membrane interactions and volatile 
hemodynamic conditions, both of which can be harmful to the homoeostasis of the 
dialysis patient.
78
 The filtration system of the hemodialysis process removes uremic 
toxins, but glucose, vitamin C, amino acids, and small peptides are also removed.
78
 The 
removal of the latter substances is undesirable and is a contributor to oxidative damage 
and subsequently, CVD. For HD patients, there are different external membranes to filter 
the blood. Yavuz et al found the polysulfone membrane to cause more oxidative stress 
compared to using a hemophan membrane as evidenced by an increased serum MDA 
concentration, and a greater decrease in GSH-Px and selenium after dialysis treatment in 
the patients using the polysulfone membrane.
75
 Interestingly, these results are 
inconsistent with previous research. Cristol et al found that after only 15 minutes of HD 
treatment, leukocytes and monocytes were activated with a cuprophane filter but not with 
a polysulfone filter.
79
 Another plausible reason for the higher incidence of oxidative 
stress in HD patients is the presence of lipopolysaccharide (LPS), a harmful endotoxin. 
Research suggests LPS in the dialysate could contribute to free radical production by 
activation of monocytes/macrophages.
80
 Lastly, oxidative stress in the dialysis patient 
may be, in part, attributable to adjuvant pharmacotherapy. Iron and erythropoietin (EPO) 
are typically given intravenously during each dialysis treatment session. Unfortunately, 
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while needed, the administration of both iron and EPO augment oxidative stress 
independently.
81, 82
 
This increase in oxidative stress with decreased immunity among HD patients is a 
basis for cardiovascular disease development. Cardiovascular disease, development 
described above, remains the primary cause of death for HD patients. The 2011 US Renal 
Data System Annual Report
1
 shows from 1997 to 1999, the percentage of deaths due to 
cardiac disease was 45. The 2007 to 2009 data shows this percentage has decreased to 39, 
although cardiac death still remains the primary cause of death. Efforts have proved 
useful as there was a 29% decline over the last ten years in CVD mortality among HD 
patients. Even so, the oxidant-antioxidant imbalance persists, resulting from a damaged 
radical scavenger system and increased production of free oxygen radicals,
78
 resulting in 
death.  
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Selenium and End Stage Renal Disease 
Selenium Status of End Stage Renal Disease Patients and its Impact on Health 
There is a large amount of research that has evaluated the selenium status in 
dialysis patients as compared to healthy subjects. In this patient population, selenium has 
been evaluated in both serum and plasma. Briefly, RBCs are absent from both plasma and 
serum, and plasma contains clotting factors while serum does not. Additionally, plasma 
and serum contain proteins (such as albumin), hormones, minerals, electrolytes, carbon 
dioxide, etc. As shown below, researchers use plasma, serum or RBC selenium to 
determine selenium status. This may, however, not be the best way to determine selenium 
status. Biologically active selenium is found as selenocysteine as part of enzymes 
requiring the compound, such as glutathione peroxidase, and measuring these enzymes is 
a functional and more highly sensitive method of selenium status.
83
 
An overwhelming majority of the research demonstrates both HD and PD patients 
present with decreased serum or plasma selenium compared to matched healthy subjects. 
Specifically, Bonomini et al, Zachara et al, and Foote et al have used cross sectional data 
to compare plasma selenium in HD patients to those of healthy controls; they have all 
found those of hemodialysis patients to be significantly lower.
14, 84, 85
 Additionally, Antos 
et al, Bogye et al, del Moral et al, and Pakfatret et al found similar results when 
comparing serum selenium of HD patients to those of healthy subjects in cross sectional 
data.
11, 86-88
 These results are not different when evaluating the difference between 
healthy adults and those undergoing PD. Apostolidis et al and Pakfetrat et al found 
patients on PD had markedly lower serum selenium than healthy controls.
11, 89
 
Interestingly, one study
89
 found a decrease in serum selenium, mentioned above, however 
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concluded there was no selenium deficiency in this population because the average 
adjusted serum-transported selenium per liter of blood was not different from the healthy 
controls. This was the only study to adjust for serum-transported selenium per liter of 
blood and the only study to date suggesting there is no discrepancy between PD patients 
and healthy people in regards to serum selenium status. Alternatively, Charney et al did 
not find a significant difference in RBC selenium values in HD patients when compared 
to healthy controls.
90
 When comparing different dialysis modalities (HD and PD) in 
relation to selenium status, Pakfetrat et al found PD patients had lower serum selenium 
compared to HD patients, suggesting selenium deficiency is more prevalent in PD 
patients.
11
 Additionally, Dworkin et al found whole blood selenium was lower in PD 
patients than HD patients.
91
 
One plausible reason for this marked decrease in plasma and serum selenium in 
dialysis patients is the loss of selenium in spent dialysis fluid. The limited amount of 
research is inconclusive. In hemodialysis patients, Pakfetrat et al found greater amounts 
of selenium in spent dialysate compared to fresh dialysate, suggesting selenium was lost 
through the HD dialysis membrane.
11
 Additionally, Bogye et al found protein along with 
selenium in the spent dialysate suggesting selenium is lost due to protein permeability in 
the HD polysulfone membrane.
87
 Along with this loss of protein and selenium in the 
spent dialysate, the researchers found no change in serum selenium prior to and after 
dialysis. However, they did find a significant increase in total serum protein after dialysis 
treatment, regardless of the increase in selenium and protein in spent dialysate. The 
authors suggest that this increase in serum protein is a result of hemoconcentration, a 
decrease in plasma volume after dialysis. On the other hand, Zachara et al reiterated 95% 
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of plasma selenium is found bound to proteins that do not cross the permeable membrane 
of the dialysis filter and thus, selenium cannot be lost during dialysis treatment.
92
 In PD 
patients, the research is limited yet more convincing. Pakfetrat et al evaluated the spent 
dialysate selenium concentration in PD patients, finding the amount of selenium in spent 
dialysate was undetectable.
11
 Additionally, when comparing fresh dialysate to spent 
dialysate in PD patients, Sriram et al found no change in dialysate selenium 
concentration.
93
 It is important to mention that while selenium is not found in spent 
dialysate, researchers have found those patients receiving PD had a greater selenium 
deficiency compared to HD patients (shown above). As mentioned above, selenium is 
mostly found as selenomethionine or selenocysteine in the blood and tissues. 
Additionally, selenomethione has a high tendency to replace methionine in the amino 
acid pool. Because many trace elements, including selenium, are bound to protein (e.g. 
selenomethionine), it has been suggested that PD patients could experience a greater loss 
of protein and thus, trace elements compared to HD patients.
93
 Lastly, another valid 
question concerning the altered serum and plasma selenium values of dialysis patients 
revolves around the reason for the altered concentration. Research has yet to demonstrate 
the biological mechanisms of if/how progressive kidney failure causes altered selenium 
status. Diskin et al suggest the selenium deficiency is a result of the primary disease, 
kidney failure, causing biochemical alterations.
94
 This biological and mechanistic 
information would contribute immensely to the body of literature and provide greater 
insight into the disease.  
To date, the majority of researchers agree that the selenium status of both PD and 
HD patients is inferior to those of their healthy counterparts. The next logical, and 
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important, concern would be to determine if the delinquency is detrimental to health. 
Researchers agree this to be case. Specifically, del Moral et al state the lower serum 
selenium levels of HD patients significantly increases the risk for CVD.
88
 Additionally, 
selenium deficiency in uremic, or end stage renal failure, patients contributes to 
cardiovascular disease, changes in immune function, and skeletal myopathies.
89, 91, 95, 96
 
While the exact mechanism is not known, it can be hypothesized that because the 
regulation of selenium stores is through the kidneys,
91
 disruption to this organ will alter 
selenium homeostasis.  
While it is clear selenium status is decreased in both HD and PD patients 
compared to healthy people and this deficiency is involved with cardiovascular disease, 
the mechanism by which this occurs is unclear. Additionally, the cause of the selenium 
deficiency is still vague and warrants further research.  
Selenium Supplementation and End Stage Renal Disease 
It is well recognized that end stage renal disease patients requiring dialysis are at 
increased risk for CVD.
97
 In fact, studies have shown both PD and HD patients to have 
decreased antioxidant status compared to their healthy counterparts. Specifically, Koenig 
et al
77
 found HD patients present with significantly elevated MDA, superoxide dismutase 
(SOD) and catalase. The authors proposed the constant increase in SOD and catalase is a 
result of the continual battle with active reactive oxygen species. Additionally, Capusa et 
al
98
 showed HD patients had significantly increased plasma thiobarbituric acid-reactive 
substances (TBARS, a consequence of lipid peroxidation), and both HD and PD patients 
had decreased total antioxidant activity and residual antioxidant activity compared to 
healthy individuals. For HD patients, it has been suggested that the production of toxins 
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as a result of the HD filtration membrane is a contributor to the decrease in patients’ 
antioxidant status,
19
 in addition to the chronic uremic state.
77
 Part of the enzymatic 
antioxidant defense system in the body includes the enzymatic action of GSH-Px which 
catalyzes the reaction of hydrogen peroxide to water, and requires selenium for its action. 
In addition to the low antioxidant status, many cross-sectional studies have revealed 
dialysis patients present with decreased plasma, serum and RBC selenium,
11, 14
 and 
decreased plasma and red blood cell GSH-Px compared to healthy counterparts.
10, 77
  
Unfortunately, relative to the amount of cross-sectional studies, very few selenium 
intervention studies have been performed. In fact, to date, only eight intervention studies 
have been completed, and all used HD patient participants. When evaluating plasma 
selenium change after selenium supplementation, it is not surprising all studies found an 
increase in plasma selenium after supplementation, as selenium is highly absorbed in the 
gastrointestinal tract. Of the eight intervention studies, five supplemented HD patients 
with selenium as either selenite or selenate,
10, 16, 77, 84, 99
 a form commonly found in 
selenium supplements. These studies ranged from 2 weeks
99
 to twenty-four weeks.
16, 84
 
Three of the five studies gave selenium supplementation during dialysis treatment (3 
times per week); however, Temple et al
99
 provided IV liquid nutrition (which included 
the supplemented selenium) as the only form of nutrition for the 2 week trial period. In 
those studies that measured GSH-Px (both plasma and/or RBC), the results varied. For 
example, Bonomini et al
84
 found an increase in whole blood GSH-Px with selenium 
supplementation compared to control, while Richard et al and Saint-Georges et al found 
an increase in both plasma and RBC GSH-Px.
10, 16
 Koenig et al
77
 found RBC GSH-Px 
and RBC selenium significantly increased after eight weeks of selenium supplementation. 
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However, Temple et al
99
 did not find any change in plasma or RBC GSH-Px after 
selenium supplementation. One plausible reason for these varying differences in GSH-Px 
is the location of the enzyme. Extracellular GSH-Px is found in the plasma while cellular 
GSH-Px is found in the RBC. Many of the studies measured RBC GSH-Px, which tended 
to increase after supplementation. Plasma, or extracellular, GSH-Px is synthesized mostly 
in the kidneys.
6
 It has been suggested that the reason the researchers are not seeing the 
desired increase in plasma GSH-Px is because the damage to the kidneys will not allow 
synthesis of the enzyme regardless of selenium status.
12, 14
  
Two of the seven intervention studies used selenium-rich yeast for 
supplementation, which contains selenium as selenomethionine, an organic form of the 
element. Zachara et al
14
 provided patients selenium-rich yeast tablets for 12 weeks and 
found supplementation increased plasma selenium but did not significantly change 
plasma GSH-Px. In another study by the same authors,
12
 patients were given selenium-
rich yeast tablets or the selenium-rich yeast tablets plus erythropoietin (EPO, a hormone 
stimulating red blood cell development) for 12 weeks. Results showed selenium 
treatments (with or without EPO) increased whole blood, plasma, and RBC selenium. An 
increase in RBC GSH-Px was seen initially but fell to baseline values by the end of the 
study, whereas plasma GSH-Px did not increase significantly in either group. All of the 
studies above supplemented with either selenite, an inorganic form of selenium, or 
selenium rich yeast (assumed to be selenium as selenomethionine). An overwhelming 
percentage of food selenium is in the form of selenomethionine or selenocysteine while 
supplemented selenium is typically an inorganic selenium source. This may be the key 
factor in determining effectiveness of selenium supplementation in dialysis patients.  
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To date, one study has used a selenium rich food source as its selenium source for 
supplementation. Stockler-Pinto et al
15
 provided hemodialysis patients with one Brazil 
nut per day for 12 weeks. Results of the study showed an increase in plasma and RBC 
selenium as well as RBC GSH-Px after selenium supplementation. The authors 
discontinued supplementation after 12 weeks however followed up with the patients 1 
year later and found plasma selenium levels had decreased since supplementation 
discontinuation however the values did not reach as low as initial study 
commencement.
15
 
Currently, selenium supplementation studies have not been performed with 
peritoneal dialysis. Additionally, long-term selenium supplementation studies have not 
been carried out to evaluate effectiveness on oxidative stress, cardiovascular disease 
outcomes/measures, or toxicity in hemodialysis and peritoneal dialysis patients. More 
research is needed using naturally high food sources for selenium “supplementation” 
within the dialysis population. Moreover, future studies need to evaluate long-term 
effects on endpoints reflecting mortality, specifically cardiovascular mortality. This 
necessary research will provide insight to sustain or alter current nutrition 
recommendations for peritoneal and hemodialysis patients. It is worth noting that most 
multivitamins prescribed for dialysis patients, including Nephrocaps, Nephrovite, and 
Dialyvite to name a few, contain vitamin C, a water soluble vitamin and potent 
antioxidant, while only some contain vitamin E, another antioxidant. Interestingly, 
neither Nephrocaps nor Nephrovite contain any selenium while four of the ten 
formulations of Dialyvite contain a trace amount of selenium. Current renal nutrition 
guidelines do not discuss selenium or selenium supplementation
100
 and in light of the 
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information above, the lack of recommendation should be reevaluated upon further 
testing.    
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Chapter 3 
METHODS 
Study Design and Subjects 
This study was a randomized, controlled trial using maintenance hemodialysis 
patients from the greater Phoenix, Arizona area. The study was approved by the Arizona 
State University Institutional Review Board (see Appendix A for Institutional Review 
Board approval). In addition, Southwest Clinical Research Institute provided written 
consent stating the Arizona State University Institutional Review Board process is 
sufficient for the research to be conducted in Southwest Kidney Institute and Davita 
dialysis clinics (see Appendix A). The goal was to enrolled thirty subjects for the study. 
Previous literature enrollment for selenium supplementation in hemodialysis patients 
ranged from 5 to 81 participants, with an average of 33 participants. Sample size 
calculation using 80% power, α at 0.05, standard deviation of 40 (based on previous 
literature) and a difference of means set at 75 (based on previous literature) determined a 
total of 6 patients per group were required for this parallel design study.  Recruitment 
took place at four dialysis facilities throughout the Phoenix, AZ and surrounding areas. 
Upon initial analysis of laboratory values from recruitment period, fifty six patients were 
identified as potential participants. Further inquisition excluded twelve of the fifty six 
participants due to possession of one or more exclusion criteria (discussed below). 
Therefore, forty-four participants were spoken to by the study investigator inquiring 
about involvement in the study. Discussion included study objectives, study procedure, 
and risks and benefit of the study. Thirty one patients decided to enroll in the study at 
which time they signed the consent form and were given a copy to keep.          
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Participants were maintenance hemodialysis patients, defined as greater than 90 
days on hemodialysis and hemodynamically stable. Eligible participants must have met 
the following criteria: a fistula or graft for hemodialysis access, >18 y of age, potassium 
value < 5.5mg/dL for at least 3 months, albumin > 3.3mg/dL for the month of screening, 
BMI (using estimated dry weight for the month of screening) < 40kg/m
2
, and free from 
HIV/AIDS, cancer and Hepatitis C. In addition, patients with antioxidant vitamin 
supplement usage within the past 90 days and/or smoking history were excluded.  
After the consent was signed by all participants, one subject revealed she smoked 
and thus, was dropped from the study. Therefore, thirty participants were randomized 
such that ten participants were to consume either two Brazil nuts per day for three 
months, swallow one tablet per day for three months, or consume three gummy bears per 
day for three months.  
Prior to study commencement, three patients dropped out from the study: two 
patients decided they did not want to participate and one subject passed away. Between 
the start of the study and the end of the first month, five participants dropped out; one 
patient experienced itching, two did not want to participate anymore, one received a 
kidney transplant, and one left the country for a family emergency. Between the first and 
second month, one participant dropped out because they did not like the taste of the 
gummy bears. Lastly, between the second and third month, one patient dropped out 
because of cancer development, one patient was lost to follow up, one patient no longer 
wanted to participate, and one patient started the study late (at month 1). Seventeen 
patients completed the study.  
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Treatment 
 Each dialysis patient was randomized to receive one of three treatments for the 3-
month intervention: 2 Brazil nuts (5g, estimated to provide 181µ/day of selenium as 
selenomethionine), 1 tablet of selenium (200µ/day of selenium as selenomethionine), or 
control (3 gummy bears/day).    
Protocol 
 After the consent was signed by the participant, a health history questionnaire was 
completed (see Appendix B). The study lasted three months and the four remaining visits 
were designated M0, M1, M2, and M3 to coincide with the participants regularly 
scheduled monthly blood draw day at the dialysis center. HD patients follow one of two 
dialysis treatment schedules: Monday/Wednesday/Friday or Tuesday/Thursday/Saturday. 
Five of the 30 patients enrolled in the study had their regularly scheduled blood draw day 
on Wednesday/Thursday while the other 25 patients had their scheduled blood draw day 
on Monday/Tuesday. The difference in absence of treatment over a 48 or 72 hour period 
will be analyzed to confirm the lack of effect on outcome variables. At visit M0 
(baseline), participants were given a compliance calendar (see Appendix B) and asked to 
place an “X” on each day they took the food product or supplement. During the four 
monthly visits, thoracic cavity fluid accumulation was measured by biothoracic 
impedance prior to dialysis treatment. During the M0, M1 and M2 visits, participants 
were provided with their experimental product. At each visit (M0, M1, M2 and M3), after 
the patient had their dialysis lines put into their arm by their respective patient care 
technician (PCT) or registered nurse (RN), three vials of blood were collected by the RN 
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or PCT and given to the study investigator for processing. Additionally, at visits M1 and 
M3, participants received a $15 gift card to Target® for their participation.  
Blood Collection and Laboratory Analysis 
Blood was collected at four time points throughout the study: month 0, 1, 2, and 
3, and was collected immediately before the participants’ dialysis session. Three tubes 
were collected from each patient. The 7mL EDTA tube was stored at room temperature 
while the 4mL EDTA and 7mL Sodium Heparin tubes were stored in the refrigerator. 
Once all subjects’ blood was collected, it was taken to the ASU laboratory for processing.  
Biomarkers measured using commercial ELISA kits included plasma and red 
blood cell glutathione peroxidase  (Cayman Chemical, Ann Arbor, MI, 
www.caymanchem.com/catalog/703102), brain natriuretic peptide (RayBiotech, 
Norcorss, GA, www.raybiotech.com/human-bnp-eia-kit.html), and total antioxidant 
capacity (Cayman Chemical, Ann Arbor, MI, www.caymanchem.com/catalog/709001). 
Plasma vitamin C was assessed using the 2,4, di-nitrophenylhydrazine spectrophotometer 
method. Plasma high density lipoprotein, low density lipoprotein, cholesterol and 
triglycerides were determined using the Cobas C 111 analyzer (F. Hoffmann-La Roche 
Lts, Switzerland).  
Conventional hemodialysis biomarkers were determined by Sonora Quest 
including serum albumin, serum potassium, and hemoglobin. Thoracic cavity fluid 
accumulation was obtained by bioimpedance (ZOE® fluid monitor, Noninvasive Medical 
Technologies, Inc., Las Vegas, NV, http://nmtinc.org/products_zoe.html). Blood pressure 
was measured at dialysis commencement by the RN or PCT.   
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Statistical Analysis 
Data are reported as mean values ± standard deviation (mean ± SD).  For cross-
sectional data at baseline, comparisons between groups was performed using a Univariate 
Analysis. Raw data are reported for each month. Two-way repeated measures ANOVA 
was used to examine changes over time and between groups at months 0 and 2 and 
months 0 and 3. In addition, intention-to-treat analysis was performed for those who 
participated in the study for only 2 months. Normality was assessed and data transformed 
prior to analyses if necessary. A p ≤ 0.05 was considered statistically significant.  All 
analyses were performed using PASW (version 19, Chicago, IL).   
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Chapter 4 
 
RESULTS 
 
Baseline Data 
 
 Thirty one participants signed the consent form on visit 1. One participant 
revealed she was a smoker after the consent form was signed and was removed from the 
study. Thirty participants were randomized to receive Brazil nuts, selenium pills, or 
gummy bears (placebo). Before study commencement, 2 participants withdrew from the 
study stating they no longer wanted to participate after speaking with family members. 
One patient died after the consent was signed but before the study started. Therefore, 27 
participants initiated the study (61.1+17.5y, 14M, 13F). Of the twenty seven participants 
that started the study, 3 were Native American (11.1%), 5 were Hispanic (18.5%), 5 were 
African American (18.5%), 12 were Caucasian (44.4%), and 2 were Asian (7.4%). Table 
1 shows the baseline characteristics of subjects by group. There were no significant 
differences between groups.  
  
Table 1. Baseline characteristics of participants within each group
1 
 
Characteristics    Nut        Pill     Placebo        p value
2
   
Gender 
   M/F   
 
5/4 
 
4/5 
 
5/4 
 
  0.862
*
 
Age (y) 57.1 + 20.2 64.2 + 16.8 62.0 + 16.5 0.694 
BMI 28.7 + 5.7 30.0 + 7.5 30.7 + 5.7 0.808 
Time on Dialysis 
(months) 35.0 + 35.1 29.1 + 13.4 40.3 + 26.0 
 
0.672 
1Data presented as mean + SD. BMI, body mass index. 
2p value represents one-way ANOVA (*p value represents chi square analysis) 
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A total of 9 dropouts were recorded (6M, 3F) during the study. The nut, pill and 
gummy group lost 5, 1, and 3 participants, respectively. Participants dropped out for the 
following reasons: complained of itching (n=1), lost to follow up (n=1), received kidney 
transplant (n=1), refused to continue participation (n=3), thought the gummy bears were 
too hard (n=1), developed melanoma (n=1), and left the country to take care of family 
(n=1). One participant in the pill group started the treatment one month late and therefore 
completed only 2 months of the study.  Thus, 17 participants completed the study in its 
entirety. There was no difference in age, body mass index (BMI), and time on dialysis in 
participants who completed the study and those that did not complete the study (p=0.565, 
p=0.564, and p=.250, respectively).   At study commencement, each participant was 
given a four-month calendar and instructed to place an “X” on days they consumed the 
food or pill. Compliance data were obtained for the 17 participants that completed the 
study. Of the study’s 98 days, the mean days compliant was 93.9 + 4.6 and did not 
significantly differ between the three groups (p=0.719). 
 After the study was initiated, 50g of Brazil nuts and 50g of the selenium pills 
were sent to an independent laboratory (Midwest Laboratories, Omaha, NE) for selenium 
analyses.  These analyses indicated that two Brazil nuts (the daily study dosage) 
contained 1µg of selenium, a value much below that listed on the National Institutes of 
Health’s dietary supplement page (181µg/2 nuts).  The analyses for the selenium tablets 
indicated that one tablet (the daily study dosage) contained 266µg, a value higher than the 
label claim, 200µg/1 tablet.  Since the study was designed assuming Brazil nuts were an 
excellent source of selenium and similar to the amount of selenium in the selenium pill, 
the nut arm of the study was, in essence, a placebo group.  Initial analyses confirmed this 
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as the change in the selenium-dependent marker, plasma glutathione peroxidase, was 
only noted for the pill group.  Hence, the gummy bear and Brazil nut arms of the study 
were collapsed, and the data hereafter are reported for the pill group (n=9) and the 
combined ‘placebo’ group (n=18) only. There remained no significant differences 
between groups for age, BMI, and time on dialysis (p=0.524, p=0.922, and p=0.427) 
between the placebo and pill groups.  Also, since 4 of the 9 participants that withdrew 
from the trial did so in the final month of the study, the decision was made to analyze 
data collected  in two ways: at baseline, month 1, and month 2 only, and intention-to-treat 
analysis for those participants that completed 2 months of the study and were lost during 
the last month of the study (n=21: 12 placebo and 9 pill). 
Antioxidant Status Outcomes 
 No significant differences were noted for plasma total antioxidant capacity 
(TAC), vitamin C (VitC), and RBC glutathione peroxidase (GSH-Px) over time or 
between the placebo (n=12) and pill groups (n=9). A trend was seen in plasma GSH-Px 
(p=0.08) for a group x time interaction. More specifically, those receiving the pill 
experienced an increase in plasma GSH-Px while those in the placebo group experienced 
a decrease in plasma GSH-Px (p=0.023 for change between month 0 and month 2). This 
significance remained when day of blood draw was controlled for (p=0.031). Table 2 
reports data for the antioxidant outcome measures, and Figure 4 shows the change from 
month 0 to month 2 for plasma and RBC GSH-Px by group; Figure 5 shows the change 
in plasma and RBC GSH-Px by group from month 0 to month 2 as well as intention-to-
treat analysis from month 0 to month 3. A significant positive correlation (r=0.599) was 
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observed for Epogen, a synthetic hormone given to stimulate RBC production, and RBC 
GSH-Px during month 2 (p<0.01) only.  
 
 
Table 2. Antioxidant status outcomes by group over time
1 
 
Variable              Pill                 Placebo   p value
2  
   ITT    Reference  
           (n=9)      (n=12)            p value
3
   Range
4
 
TAC (mM)     1.0-2.30 
  month 0 1.73 + 0.7 1.61 + 0.8    
  month 1 1.59 + 0.6 1.81 + 0.7    
  month 2 2.21 + 0.7 2.09 + 0.6 0.708
*
   
  month 3 1.80 + 0.7 1.66 + 0.6  0.896
*
  
VitC (µg ascorbic 
acid/ml) 
    0.50-2.0† 
  month 0 0.38 + 0.35 0.26 + 0.27    
  month 1 0.24 + 0.20 0.24 + 0.18    
  month 2 0.25 + 0.17 0.28 + 0.25 0.277
‡
   
  month 3 0.26 + 0.2 0.27 + 0.2  0.422
‡
  
RBC GSH-Px (U/g Hb)     20.0-71.0 
  month 0 66.8 + 18.5 72.5 + 16.2    
  month 1 63.5 + 19.6 73.3 + 18.0    
  month 2 69.2 + 17.5 70.4 + 15.1 0.409   
  month 3 71.5 + 16.1 67.7 + 16.0  0.147  
Plasma GSH-Px 
(nmol/min/ml)    
 38.0-51.0 
  month 0 39.8 + 7.9 47.6 + 13.9    
  month 1 42.2 + 9.6 41.8 + 13.5    
  month 2 45.8 + 11.6 43.7 + 11.5 0.023   
  month 3 41.4 + 10.9 42.5 + 11.4  0.193
‡
  
1Data presented as mean + SD, n = 21. Univariate analysis indicated no differences at baseline.  ITT, intention to treat; TAC, total 
antioxidant capacity; VitC, vitamin C; RBC GSH-Px, red blood cell glutathione peroxidase; Plasma GSH-Px, plasma glutathione 
peroxidase. Assessing for confounders (gender, age, BMI, and time on dialysis) revealed 2 associations: TAC and time on dialysis (r=-
0.528, p=0.014) and VitC and BMI (r=-0.550, p=0.010). 
2 p value represents two-way repeated measures ANOVA for the group x time interaction at months 0 and 2.  
3 p value represents two-way repeated measures ANOVA for the group x time interaction at months 0 and 3. 
4Reference standard not established. Ranges indicative of healthy population in recent literature (†reference standard established). 
*Covariate controlled for in analyses.  
‡Data not normally distributed hence p value for Mann-Whitney analyses change between 0 and 2 months. 
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Figure 4. Change in glutathione peroxidase by group (data represents change + SE) 
*p=0.023 between groups 
 
 
 
Figure 5. Change in glutathione peroxidase by group with intention-to-treat data analysis 
(data represents change + SE) 
*p=0.023 between groups 
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Cardiovascular Disease (CVD) Outcomes 
 The CVD outcome variables [brain natriuretic peptide (BNP); plasma cholesterol 
(CHOL), high density lipoprotein (HDL), low density lipoprotein (LDL), triglyceride 
(TG); systolic and diastolic blood pressure (BP); and thoracic cavity fluid accumulation 
(TCFA, lower values indicate more fluid accumulation in the thoracic cavity) values] did 
not change significantly over time or between groups during the study (Table 3).   
Traditional Hemodialysis Markers 
 
 There were no statistical differences between groups or over time for serum 
albumin or serum potassium (Table 4), two traditional biomarkers measured monthly at 
dialysis units. Additionally, serum potassium remained within normal limits throughout 
the study despite providing patients with nuts, a higher source of potassium in the food 
supply. C-reactive protein is a marker for inflammation and is part of the dialysis 
monthly blood report. Baseline value correlation analysis shows significant negative 
correlation with HDL (r=-0.402, p=0.037) suggesting as inflammation worsens, HDL 
decreases. Alternatively, a significant positive correlation was seen with TG and C-
reactive protein (r=0.576, p=0.002); Table 5 shows baseline correlations with C-reactive 
protein and plasma HDL, TG and albumin. 
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Table 3. Cardiovascular disease outcomes by group over time
1
 
 
Variable  Pill    Placebo    p value
2
             ITT        Reference 
           (n=9)     (n=12)     p value
3
       Range
† 
BNP (pg/ml)     <100 
  month 0 248.5 + 164.9 258.5 + 101.3    
  month 1 240.1 + 103.6 230.4 + 66.0    
  month 2 242.3 + 139.0 300 + 99.3 0.382
‡ 
  
  month 3 238.7 + 120.5 240.9 + 42.1  0.754
‡
  
CHOL 
(mg/dl) 
  
 
 <200 
  month 0 124.2 + 40.1 147.6 + 21.3    
  month 1 143.6 + 47.2 145.2 + 33.7    
  month 2 140.8 + 35.3 151.8 + 31.1 0.216   
  month 3 136.5 + 33.2 147.2 + 27.9  0.140  
HDL (mg/dl)     >60 
  month 0 43.8 + 8.7 47.3 + 24.8    
  month 1 43.5 + 13.4 45.9 + 18.3    
  month 2 41.8 + 8.6 50.5 + 27.4 0.169
‡
   
  month 3 41.7 + 9.2 47.5 + 24.8  0.554
‡
  
LDL (mg/dl)     <100 
  month 0 69.1 + 37.6 77.3 + 24.0    
  month 1 79.6 + 41.7 74.5 + 28.1    
  month 2 78.8 + 30.1 75.5 + 31.2 0.219
‡
   
  month 3 73.7 + 27.8 73.0 + 30.1  0.219
‡
  
1Data presented as mean + SD, n = 21. Univariate analysis indicated no differences at baseline. ITT, intention to treat; BNP, brain 
natriuretic peptide; CHOL, cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; TG, triglyceride; BP, blood 
pressure; TCFA, thoracic cavity fluid accumulation. Assessing for confounders (gender, age, BMI, and time on dialysis) revealed 4 
association: HDL and gender (M: 35.5 + 10.9, F: 57.2 + 20.5, p=0.006), HDL and BMI (r=-0.458, p=0.037), Diastolic BP and age (r=-
0.666, p=0.001), and TCFA and BMI (r=0.436, p=0.048).  
2 p value represents two-way repeated measures ANOVA for the group x time interaction at months 0 and 2.  
3p value represents two-way repeated measures ANOVA for the group x time interaction at months 0 and 3.  
 4n=19 (placebo = 11, pill = 8) 
†reference standard established.  
‡Data not normally distributed hence p value for Mann-Whitney analyses change between 0 and 2 months.  
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Table 3 continued. Cardiovascular disease outcomes by group over time
1
 
 
Variable  Pill   Placebo    p value
2
       ITT           Reference 
           (n=9)    (n=12)          p value
3
           Range
† 
TG (mg/dl)     <150 
  month 0 96.2 + 28.7 149.6 + 80.0    
  month 1 126.8 + 54.5 157.6 + 68.6    
  month 2 129.0 + 36.0 159.5 + 98.8 0.297   
  month 3 141.9 + 45.6 166.1 + 87.3  0.118  
Systolic BP     <120 
  month 0 150.8 + 80.7 143.2 + 26.6    
  month 1 146.6 + 23.7 134.9 + 22.7    
  month 2 154.8 + 32.8 138.2 + 20.5 0.390   
  month 3 144.6 + 26.8 141.6 + 16.0  0.706  
Diastolic BP     <80 
  month 0 72.4 + 8.8 78.6 + 21.6    
  month 1 78.0 + 24.5 79.1 + 19.1    
  month 2 71.2 + 14.5 83.1 + 17.8 0.166
*
   
  month 3 73.2 + 19.5 81.9 + 18.8  0.493
*
  
TCFA 
(ohms)
4 
  
  19.0-30.0 
  month 0 30.0 + 5.5 30.4 + 5.2    
  month 1 30.8 + 6.7 30.0 + 5.4    
  month 2 29.0 + 7.1 29.6 + 4.8 0.859   
  month 3 28.0 + 6.6 27.2 + 4.9  0.517
*
  
1Data presented as mean + SD, n = 21. Univariate analysis indicated no differences at baseline. ITT, intention to treat; BNP, brain 
natriuretic peptide; CHOL, cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; TG, triglyceride; BP, blood 
pressure; TCFA, thoracic cavity fluid accumulation. Assessing for confounders (gender, age, BMI, and time on dialysis) revealed 4 
association: HDL and gender (M: 35.5 + 10.9, F: 57.2 + 20.5, p=0.006), HDL and BMI (r=-0.458, p=0.037), Diastolic BP and age (r=-
0.666, p=0.001), and TCFA and BMI (r=0.436, p=0.048).  
2 p value represents two-way repeated measures ANOVA for the group x time interaction at months 0 and 2.  
3p value represents two-way repeated measures ANOVA for the group x time interaction at months 0 and 3.  
 4n=19 (placebo = 11, pill = 8) 
†reference standard established.  
*Covariate controlled for in analyses. 
‡Data not normally distributed hence p value for Mann-Whitney analyses change between 0 and 2 months.  
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Table 4. Traditional hemodialysis markers by group over time
1
 
 
Variable    Pill    Placebo    p value
2
             ITT        Reference 
             (n=9)     (n=12)     p value
3
       Range
†
 
Serum Albumin 
(g/dL) 
    >4.0 
  month 0 3.7 + 0.5 3.9 + 0.2    
  month 1 3.7 + 0.6 3.9 + 0.3    
  month 2 3.7 + 0.6 4.0 + 0.3 0.153   
  month 3 3.7 + 0.6 3.9 + 0.2  0.828  
Serum Potassium 
(mEq/L) 
  
 
 3.5-5.5 
  month 0 4.4 + 0.4 4.8 + 0.9    
  month 1 4.7 + 0.4 4.7 + 0.7    
  month 2 5.0 + 0.8 5.0 + 0.6 0.263   
  month 3 4.6 + 0.4 4.9 + 0.6  0.813  
1Data presented as mean + SD, n = 21. Univariate analysis indicated no differences at baseline. ITT, intention to treat.  
2 p value represents two-way repeated measures ANOVA for the group x time interaction at months 0 and 2.  
3p value represents two-way repeated measures ANOVA for the group x time interaction at months 0 and 3.  
†reference standard established.  
 
 
 
Table 5. Baseline Correlations of CRP and albumin, TG, and HDL
1
 
  
Variable     Value          correlation (r)   p value
2
 
hs-CRP (mg/L) 9.7 + 10.9   
Serum Albumin (g/dL) 3.9 + 0.4 -0.338 0.084 
Serum TG (mg/dL) 122.8 + 62.1 0.576 0.002 
Serum HDL (mg/dL) 46.7 + 20.2 -0.402 0.037 
1Data presented as mean + SD, n = 27. hs-CRP, high-sensitivity C-reactive protein; TG, triglycerides; HDL, high density lipoprotein 
2 p value represents correlation.  
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Chapter 5 
 
DISCUSSION 
 
These data demonstrate that selenium supplementation from a pill may be 
beneficial in improving plasma glutathione peroxidase in maintenance hemodialysis 
patients. The lack of selenium found in the Brazil nut is unfortunate. The Brazil nut is 
purported to be the highest source of selenium in the human diet however our 
independent analysis showed the nuts to be almost void of selenium, despite being grown 
in Bolivia. The reliability of Brazil nuts as a good source of selenium is questionable and 
should be used with caution.    
Antioxidant Status Outcomes 
We demonstrated an increase in plasma GSH-Px, a selenium dependent enzyme 
synthesized by the kidney,
6
 after two months of treatment in the group receiving 266µg 
of selenium as selenomethionine per day; however, values remained within the normal 
range and the significance was lost after intention-to-treat analysis for three months was 
performed. Only two previously published selenium interventions
10, 16
 have shown an 
improvement in plasma GSH-Px in hemodialysis patients, and both used selenite, an 
inorganic form of selenium. Notably, Saint-Georges et al provided patients with 500µg of 
selenium orally three times per week after dialysis treatment for 3 months and then 
reduced the amount to 200µg for the following 3 months. When the amount of selenium 
was reduced, the levels of plasma GSH-Px did not return to baseline and in fact, 
remained elevated.
16
 Conversely, Richard et al provided patients with 50µg intravenously 
for 5 weeks and then increased to 100µg for the following 15 weeks. They saw an 
increase in both plasma and RBC GSH-Px.
10
 This suggests a smaller dose of selenium 
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through intravenous injection may be as potent as a larger dose of selenium given orally. 
Alternatively, Temple et al and Zachara et al
12, 14, 99
 did not show an increase in plasma 
GSH-Px after selenium supplementation using an inorganic and organic form of 
selenium, respectively. Notably, Zachara et al
14
 stated this was a result of the damaged 
kidney’s inability to synthesize the enzyme. Unlike plasma GSH-Px, most selenium 
supplementation research in hemodialysis patients has shown supplementation to 
improve RBC GSH-Px
10, 12, 15, 16, 77, 84
 with the exception of one.
99
 The studies that 
showed an increase in the enzyme were at least 2 months in duration, which is enough 
time to see red blood cell turnover in 2/3 of the body’s pool, as the lifespan of the RBC is 
3 months. This is a necessary step when evaluating change in RBC GSH-Px as selenium 
is incorporated into the newly formed RBC during erythropoiesis.
101
 In a study lasting 3 
month, Zachara et al
12
 provided patients either erythropoietin, selenium as 
selenomethionine (300µg 3x/week), or erythropoietin plus selenium for 3 months. An 
increase in RBC GSH-Px was seen in both selenium groups (with and without 
erythropoietin) however not in the erythropoietin group alone. In our study, a significant 
positive correlation was found between RBC GSH-Px and erythropoietin given in month 
2 only (r=0.599, p=0.007). This coincides with previous research although we did not 
find a significant difference between groups. It is noteworthy to mention that although we 
did not see a significant increase in RBC GSH-Px in the pill group, an increase was 
demonstrated, from 66.8 to 69.2 U/g Hbg. Conversely, the placebo groups experienced a 
decline in RBC GSH-Px, from 72.5 to 70.4 U/g Hbg. This may suggest a protective effect 
of the selenium pill compared to the control and a higher dose of selenium may have been 
needed to see improvement. Lastly, it should be taken into consideration that RBC GSH-
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Px is expressed as units/g of hemoglobin and that hemoglobin concentration of dialysis 
patients is lower than in healthy individuals,
102, 103
 possibly inflating the value of RBC 
GSH-Px of our study population. In fact, the RBC GSH-Px of our study population was 
within the reference range, and at some points, above the range.   
We are the first study to evaluate selenium supplementation on TAC in 
maintenance hemodialysis patients. Our results showed no difference on TAC by 
treatment group and over time. Previous research evaluating TAC in HD patients 
compared to healthy controls varies. TAC has been found to be higher in HD patients 
compared to healthy controls before dialysis treatment
104-107
 but has also been found to be 
lower.
108
 Additionally, TAC has been shown to fluctuate before and after treatment. More 
specifically, TAC has shown increases
108
 or decreases
104, 106
 post dialysis treatment 
compared to pre dialysis treatment. The TAC assay does not differentiate between the 
various antioxidants in the sample, which include glutathione, ascorbic acid, vitamin E, 
bilirubin, trolox, bovine serum albumin (BSA) and uric acid. Researchers have suggested 
the higher TAC levels in HD patients compared to healthy controls can be attributed to 
their elevated uric acid concentration, as uric acid is excreted by the kidney.
106
 While uric 
acid does not dissipate superoxide, it does require ascorbic acid and thiols to function 
properly.
109
 Alternatively, it has been suggested the elevated TAC levels is not solely 
because of the uric acid content, but could be a result of the thiols or other substances that 
have not been identified yet.
107
 Despite the reason, the elevation of TAC in HD patients 
may help protect against the increased oxidative stress these patients undergo.  
We did not see a significant change in plasma ascorbic acid by treatment group or 
over time. When ascorbate, or reduced vitamin C, is oxidized, it is converted to 
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semidehydroascorbate and further to dehydroascorbate, the oxidized form of vitamin C. 
The interplay between ascorbate, semidehydroascorbate and dehydroascorbate, and the 
regeneration of vitamin C, is made possible by both enzyme-dependent and independent 
pathways, including semidehydroascorbate reductase, an NADH-dependent enzyme, 
required for the regeneration of ascorbic acid.
110
 Vitamin C does not rely solely on GSH 
systems to regenerate, which may be the cause for  the lack of change in vitamin C 
throughout the study. Alternatively, vitamin E requires ascorbic acid and GSH systems to 
regenerate in the lipid membrane. The oxidant-antioxidant imbalance in hemodialysis 
patients is evident by the low plasma vitamin C levels of our study participants. The 
extracorporeal filtration system used by hemodialysis patients has been suggested to 
contribute to increased oxidation, further exacerbating the oxidant-antioxidant imbalance. 
Furthermore, it has been suggested the hemodiafiltration with ultrafiltrate induces less 
oxidative stress compared to the polysulfone membrane.
111
 
Cardiovascular Disease Outcomes 
Our results did not show a significant change in brain natriuretic peptide (BNP) 
between groups or over time. BNP is a 32 amino acid bioactive peptide that is 
synthesized by the cardiomyocytes and released during hemodynamic stress.
18
 It is 
generally accepted that renal patients present with higher levels of the hormone compared 
to healthy individuals,
112-114
 increasing progressively as the disease worsens
114
, due to 
their inability to clear the hormone as it is normally excreted by the kidneys.
18
 In fact, 
both dialysis dependent and non-dialysis dependent CKD patients present with elevated 
BNP and plasma levels are correlated with increased left ventricular mass.
115
 Our patient 
population had a higher level of BNP than normal (<100pg/ml) however this may be, in 
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part, due to the kidneys inability to excrete the hormone. In addition, an increase of BNP 
is also seen in the elderly.
18
 Since the average age of our sample was 61y, this could be 
another plausible reason for increased levels. The elevated level of BNP is predictive of 
increased mortality. DeFilippi et al showed CKD patients with a glomerular filtration rate 
of <60mL/min/1.73m
2
 (CKD stage 3-5) and a BNP of >800ng/l (equivalent to 800pg/ml) 
with a 260% increased risk of mortality (p=0.004) after adjustment for typical descriptors 
(i.e. age, sex, etc.) and various comorbidities (i.e. hypertension, heart failure, etc.).
113
  
Our study did not show a change in any of the lipid biomarkers, including low 
density lipoprotein (LDL), high density lipoprotein (HDL), cholesterol (CHOL), 
triglycerides (TG), systolic blood pressure (sBP), or diastolic BP (dBP). According to the 
National Cholesterol Education Program Adult Treatment Panel (ATP) III, an optimal 
lipid panel would consist of the following: LDL < 100mg/dL, HDL > 60mg/dL, and total 
cholesterol < 200mg/dL.
116
 In addition, a triglyceride level of < 150 mg/dL
117
 and a blood 
pressure of <120/80 mm Hg
118
 is optimal. Interestingly, the blood pressure treatment 
guidelines are slightly altered with CKD patients, such that CKD patients require 
aggressive medication therapy and should be treated with 3 antihypertensive medications 
if sBP exceeds 130 mg/dL and/or if dBP exceeds 80 mg/dL.
118
 The participants in our 
study had CHOL, LDL, TG, and dBP within the normal limits of healthy adults. The 
monthly average for each group had an HDL of above 40 mg/dL but was slightly less 
than optimal (>60 mg/dL). In addition, their sBP was above the recommended 120 mm 
Hg. This is most likely due to each patient’s medication regimen, as 23 of the 27 patients 
that initiated the study were taking a lipid lowering medication and/or antihypertensive 
medication. Our patients did, however, present with elevated C-reactive protein (CRP), a 
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clinical marker of inflammation. Our data is in line with previous research, such that 
Stage 5 CKD patients present with elevated CRP levels
119
, and that in the Stage 5 CKD 
patient population, CRP is a strong predictor of coronary heart disease.
120
 
An overwhelming majority of research has shown clinical effectiveness of statin 
therapy (i.e.: lowering of low density lipoprotein and total cholesterol) in CKD patients, 
including those on dialysis.
121-123
 Unfortunately, this lipid lowering effect has not always 
shown beneficial effects in improving stroke, cardiovascular death, and nonfatal 
myocardial infarction.
124
 In fact, a study involving 2776 maintenance hemodialysis 
patients found a significant decrease in LDL (43% from baseline) after only three months 
of therapy in those that received 10mg of Rosuvastatin daily. However, a median follow 
up period of 3.8 years showed statin administration did not affect the primary endpoints 
of the study: nonfatal stroke, nonfatal myocardial infarction, or cardiovascular death. 
Additionally, there was no significant effect on all-cause mortality between the placebo 
and treatment groups.
125
  
Limitations 
Three major limitations were observed during the course of this study. The first 
limitation is the debilitating amount of selenium found in the Brazil nuts. As mentioned 
above, this is unfortunate due to Brazil nuts supposedly being the highest food source of 
selenium. Due to the variability of selenium in the soil, the amount of selenium in Brazil 
nuts will continue to vary tremendously and this may be difficult to control for in future 
research studies. The second limitation of this study was the rather high attrition rate. We 
experienced a loss of 13 participants after the consent was signed. The highest attrition 
was seen in the nut group where 6 participants were lost, followed by the placebo group 
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and pill group who lost 4 and 3 participants, respectively. It is important to note there 
were no adverse events reported as a result of the study, and the reason for the high 
attrition was unrelated to the study design or food consumed. The high attrition can be 
expected with research conducted in a severely diseased population. Sample size 
calculations described above, showed 12 participants would be required for statistical 
power in this study. After the study was completed and an accurate standard deviation of 
the outcome variable and difference of means was determined for our study population, 
power analysis was calculated at 81 participants per group. The third limitation was 
limited amount of markers measured. Ideally, markers of lipid peroxidation and troponin 
T, a marker associated with cardiovascular death and heart failure in the general 
population and the CKD population, 126 would have been measured during this study to 
provide a more comprehensive picture regarding the effect of selenium supplementation 
on the oxidant-antioxidant imbalance. In addition, measuring vitamin E would have also 
been beneficial in determining lipid membrane stability and vitamin C usage in its 
regeneration. Due to financial constraints, these markers were not able to be analyzed.  
Future Research 
Future research evaluating selenium supplementation in hemodialysis patients 
should be cautious using a food source, specifically when using Brazil nuts. In fact, to 
ensure that patients are receiving the purported amount of selenium, a supplement should 
be used. This study found an increase in plasma GSH-Px using an oral supplement of 
organic selenium as selenomethionine. It would be interesting to compare and contrast 
the effects of an organic form of selenium to an inorganic form of selenium on plasma 
GSH-Px. Furthermore, future research should provide a cocktail of antioxidants. When 
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humans consume food, they consume a plethora of nutrients, not a single nutrient. 
Because the antioxidant system relies heavily on vitamin C, noting the effects of 
selenium and vitamin C supplementation in maintenance hemodialysis patients would be 
useful in determining its effect on overall antioxidant status. Our study measured BNP as 
a marker for heart failure. Literature has shown BNP’s precursor, N-terminal fragment 
BNP (NT-pro-BNP), has a longer half-life and therefore may be a more accurate 
indicator of cardiac stress.
18
 Lastly, there is void in the literature evaluating selenium 
supplementation in peritoneal dialysis patients. In fact, there are no published trials to 
date. Future research should evaluate the effect of selenium and vitamin C 
supplementation in peritoneal dialysis patients to improve antioxidant status.    
Conclusion 
 Results from this study suggested 266µg/day of selenium as selenomethionine 
from a tablet consumed for three months increase plasma GSH-Px in maintenance 
hemodialysis patients. In addition, the low vitamin C status in conjunction with selenium 
supplementation may have the potential to improve antioxidant status in hemodialysis 
patients however more research is warranted.    
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TABLE 6. Antioxidant status outcomes by group over time
1 
 
Variable             Pill           Nut        Placebo   p value
2 
    Reference  
         (n=7)           (n=4)          (n=6)                  Range
3 
TAC (mM)     1.0-2.30 
  month 0 1.7 + 0.3 1.7 + 1.2 1.4 + 0.6   
  month 1 1.4 + 0.6 2.2 + 0.6 1.6 + 0.7   
  month 2 2.2 + 0.8 2.1 + 0.6 2.2 + 0.8   
  month 3 1.7 + 0.8 1.8 + 0.8 1.5 + 0.6 0.267  
VitC  
(µg ascorbic acid/ml) 
    0.50-2.0† 
  month 0 0.30 + 0.25 0.45 + 0.44 0.17 + 0.07   
  month 1 0.27 + 0.21 0.35 + 0.30 0.17 + 0.07   
  month 2 0.26 + 0.18 0.43 + 0.42 0.20 + 0.07   
  month 3 0.28 + 0.21 0.41 + 0.34 0.20 + 0.09 0.526
‡
  
RBC GSH-Px  
(U/g Hb)     
20.0-71.0 
  month 0 75.5 + 7.5 84.8 + 14.7 62.0 + 12.3   
  month 1 67.4 + 20.8 89.0 + 12.3 60.8 + 14.9   
  month 2 73.3 + 17.3 81.7 + 11.1 61.4 + 13.8   
  month 3 76.2 + 14.3 72.9 + 11.4 61.8 + 19.3 0.031  
Plasma GSH-Px 
(nmol/min/ml)     
38.0-51.0 
  month 0 39.5 + 6.0 46.1 + 9.3 44.4 + 13.7   
  month 1 43.2 + 10.7 44.6 + 10.8 36.2 + 10.1   
  month 2 48.5 + 11.6 42.4 + 8.2 40.6 + 6.8   
  month 3 42.8 + 11.8 37.6 + 5.1 41.7 + 6.6 0.065  
1Data presented as mean + SD, n = 17. Univariate analysis indicated no differences at baseline. TAC, total antioxidant capacity; VitC, 
vitamin C; RBC GSH-Px, red blood cell glutathione peroxidase; Plasma GSH-Px, plasma glutathione peroxidase. Assessing for 
confounders (gender, age, EDW, and time on dialysis) revealed no associations. 
2 p value represents two-way repeated measures ANOVA for the group x time interaction. *Covariate controlled for in analyses. ‡Data 
not normally distributed hence p value for Kruskal-Wallis analyses change between 0 and 3 months 
3Reference standard not established. Ranges indicative of healthy population in recent literature (†reference standard established). 
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TABLE 7. Cardiovascular disease outcomes by group over time
1
 
 
Variable      Pill        Nut                              Placebo                       p value2             Reference 
   (n=7)                     (n=4)                       (n=6)                               Range† 
BNP (pg/ml)     <100 
  month 0 
210.5 + 87.4 266.4 + 47.3 279.6 + 134.2 
  
  month 1 
228.7 + 84.3 229.7 + 14.7 249.3 + 88.3 
  
  month 2 
215.9 + 114.1 242.2 + 39.7 341.1 + 124.1 
  
  month 3 211.3 + 79.6 241.5 + 38.1 223.2 + 31.1 0.387‡  
CHOL (mg/dl)     <200 
  month 0 
133.8 + 40.8 147.5 + 3.5 149.1 + 31.1  
 
  month 1 
152.3 + 49.2 153.3 + 28.7 145.8 + 42.3  
 
  month 2 
149.8 + 33.4 159.6 + 23.7 154.8 + 37.4  
 
  month 3 144.2 + 32.1 151.8 + 13.2 151.1 + 36.4 
0.435 
 
HDL (mg/dl)    
 
>60 
  month 0 
46.5 + 8.0 59.8 + 38.1 40.7 + 12.5  
 
  month 1 
48.1 + 11.4 57.3 + 26.7 40.1 + 7.5  
 
  month 2 
44.1 + 8.3 67.0 + 43.9 42.5 + 9.0  
 
  month 3 
44.1 + 9.1 62.1 + 39.2 39.9 + 9.3 0.744‡ 
 
LDL (mg/dl)    
 
<100 
  month 0 
75.7 + 40.7 65.6 + 13.3 88.4 + 29.3  
 
  month 1 
87.8 + 42.2 67.7 + 18.5 84.3 + 35.8  
 
  month 2 
86.9 + 28.8 64.5 + 25.8 88.9 + 35.6  
 
  month 3 
80.3 + 26.8 59.4 + 23.4 87.3 + 34.1 0.532‡ 
 
TG (mg/dl) 
    
<150 
  month 0 
102.5 + 29.7 142.8 + 112.0 131.9 + 44.8 
  
  month 1 
113.3 + 41.6 184.6 + 85.2 133.6 + 67.7 
  
  month 2 
125.0 + 34.8 178.7 + 174.6 139.8 + 47.2 
  
  month 3 
141.5 + 48.5 183.8 + 152.2 149.7 + 46.3 
0.449  
Systolic BP 
   
 <120 
  month 0 
150.0 + 22.3 129.8 + 26.1 154.2 + 24.8 
  
  month 1 
141.9 + 25.0 121.0 + 15.6 147.5 + 24.2 
  
  month 2 
162.7 + 30.7 133.5 + 7.3 141.3 + 28.2 
  
  month 3 
149.6 + 25.8 143.3 + 13.5 141.7 + 19.5 
0.271  
Diastolic BP 
   
 <80 
  month 0 
71.7 + 9.2 82.0 + 30.1 79.5 + 19.0 
  
  month 1 
74.9 + 25.1 76.3 + 14.4 84.0 + 23.5 
  
  month 2 
76.1 + 9.4 81.8 + 17.8 81.2 + 12.1 
  
  month 3 
78.7 + 16.9 84.5 + 17.4 77.0 + 14.2 
0.581*  
TCFA (ohms)3 
   
 19.0-30.0 
  month 0 
31.8 + 4.0 31.3 + 1.6 31.7 + 6.4 
  
  month 1 
33.0 + 5.1 28.8 + 5.7 32.4 + 5.4 
  
  month 2 
31.1 + 5.8 30.9 + 2.0 31.2 + 4.7 
  
  month 3 
31.4 + 3.7 29.5 + 4.0 26.9 + 5.0 
0.053  
1
Data presented as mean + SD, n = 17. Univariate analysis indicated no differences at baseline BNP, brain natriuretic peptide; CHOL, cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; TG, 
triglyceride; BP, blood pressure; TCFA, thoracic cavity fluid accumulation. Assessing for confounders (gender, age, EDW, and time on dialysis) revealed 2 association: HDL and gender (M: 37.3 + 12.1, F: 56.8 + 
22.7, p=0.013) and Diastolic BP and age (r=-0.561, p=0.004). 
2 
p value represents two-way repeated measures ANOVA for the group x time interaction. *Covariate controlled for in analyses. 
 ‡
Data not normally 
distributed hence p value for Kruskal-Wallis analyses change between 0 and 3 months. 
†
reference standard established. 
3
n=14 
